The development of mature blood cells from haematopoietic stem cells has long served as a
model for stem-cell research, with the haematopoietic differentiation tree being widely used …

Cellular metabolism in hematopoietic stem cells (HSCs) is an area of intense research
interest, but the metabolic requirements of HSCs and their adaptations to their niches during …

Haematopoietic stem cells (HSCs) are a rare cell type that reconstitute the entire blood and
immune systems after transplantation and can be used as a curative cell therapy for a variety …

The inaccessibility of living bone marrow (BM) hampers the study of its pathophysiology
under myelotoxic stress induced by drugs, radiation or genetic mutations. Here, we show …

Sickle cell disease (SCD) is the most common serious monogenic disease with 300,000
births annually worldwide. SCD is an autosomal recessive disease resulting from a single …

The ability to expand hematopoietic stem and progenitor cells (HSPCs) ex vivo is critical to
fully realize the potential of HSPC-based therapies. In particular, the application of clinically …

Hematopoietic stem cell (HSC) self-renewal and aging are tightly regulated by paracrine
factors from the bone marrow niche. However, whether HSC rejuvenation could be achieved …

The β-haemoglobinopathies, such as sickle cell disease and β-thalassaemia, are caused by
mutations in the β-globin (HBB) gene and affect millions of people worldwide. Ex vivo gene …

Targeted gene editing in hematopoietic stem cells (HSCs) is a promising treatment for
several diseases. However, the limited efficiency of homology-directed repair (HDR) in …

The growing clinical success of hematopoietic stem/progenitor cell (HSPC) gene therapy
(GT) relies on the development of viral vectors as portable" Trojan horses" for safe and …